GOLDENWELL BIOTECH, INC. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Goldenwell Biotech, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
Goldenwell Biotech, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 556 %, a 1382% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	556	+518	+1382%	Sep 30, 2024
Q2 2024	229	+205	+856%	Jun 30, 2024
Q1 2024	109	+90.6	+480%	Mar 31, 2024
Q4 2023	65.6	+49.9	+317%	Dec 31, 2023
Q3 2023	37.5	+12.6	+50.3%	Sep 30, 2023
Q2 2023	23.9	-9.96	-29.4%	Jun 30, 2023
Q1 2023	18.9	-22.3	-54.1%	Mar 31, 2023
Q4 2022	15.7	-23.9	-60.3%	Dec 31, 2022
Q3 2022	25	-4.04	-13.9%	Sep 30, 2022
Q2 2022	33.9	+15.6	+85.6%	Jun 30, 2022
Q1 2022	41.1			Mar 31, 2022
Q4 2021	39.6			Dec 31, 2021
Q3 2021	29			Sep 30, 2021
Q2 2021	18.3			Jun 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.